

Reason for Transfer:

Protocol closure

Office of Sponsor and Regulatory Oversight	Document #:	F01-501-S08
Lucrosticoticus I Duradoust Turousfou Authoricaticus	Revision #:	1
Investigational Product Transfer Authorization	Effective Date:	16111112022

Date Form Completed	l:				
Responsible Parties:					
	Transferer	Receiver		Additional Inf	formation (if applicable)*
Investigator of Record (IOR) Name:					
IOR Telephone:					
IOR Email:					
Protocol Number:					
*Contact information in c	case of site-to-site and	d/or NIH to non-NIH trans	iters.		
Investigational Product		Item 2	Item 3		Item 4
	c(s):				Item 4
Investigational Product Drug Name:	c(s):				Item 4
Investigational Product Drug Name: IDMS Lot #:	c(s):				Item 4
Investigational Product Drug Name: IDMS Lot #: Manufacturer:	c(s):				Item 4
Investigational Product Drug Name: IDMS Lot #: Manufacturer: Manufacturer Lot #:	i(s):				Item 4

Confidential Page 1 of 2

Other (specify):

IP expiration



2.

Office of Sponsor and Regulatory Oversight

Investigational Product Transfer Authorization

Revision #:

1

Effective Date: 16JUN2023

ection 1 completed by:	
Transferring IOR Approval:	Receiving IOR Approval:
ection to be completed by OSRO Pharmaceu	itical Management and/or designee.
Drug accountability log and reported cu	rrent inventory match
IP storage temperature logs have been r	reviewed for temperature excursions, if applicable
Manufacturer and/or supplier has given	authorization for the transfer, if applicable
Section 2 completed by:	
Transfer request approved by:	

Note: Copies of the signed form are to be provided to the transferring IOR, the receiving IOR and the current site storage location.

Confidential Page 2 of 2